Published in

American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(36), p. TPS9605-TPS9605

DOI: 10.1200/jco.2018.36.15_suppl.tps9605

Links

Tools

Export citation

Search in Google Scholar

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.

Journal article published in 2018 by Shailender Bhatia, Andrew Scott Brohl, Isaac Brownell, Sunandana Chandra, Sumia Dakhil, Marc S. Ernstoff, Leslie Anne Fecher, Ted Gooley, Glenn J. Hanna, Reina Hibbert, Ciara Marie Kelly, Samantha M. Kiriluk, Paul Nghiem ORCID, Vivian Nguyen, Nichole Pelz and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO